This page shows all past and ongoing consultations towards EPF has committed to submit a response jointly with its members. You can access the draft responses and add your comments by clicking on the appropriate link. This page is restricted to Members only.


EU Commission Pharmaceutical Strategy

The draft pharmaceutical strategy of the European Commission is currently out for public consultation. The consultation is open until 15 September 2020. Access to and affordability of medicines is one of the stated health policy priorities of the European Commission. EPF is preparing a response, based on our previous policy work and our analysis of the Roadmap for the pharmaceutical strategy, on which we submitted initial comments in July.

More information:
EPF Draft response:

Please submit your comments by: 8 September 2020


Digital Education Plan

The European Commission has launched an EU-wide public consultation to gather the views of citizens and stakeholders on the future of digital education during the COVID-19 recovery period and beyond. The consultation will contribute to the Commission’s proposal for a renewed Digital Education Action Plan, expected in September 2020. Digital transformation is one of the Commission’s priorities as set out in its flagship strategy, A Europe fit for the digital age. The new Digital Education Action Plan will form a key aspect of the Next Generation EU recovery instrument. The Action Plan will support Member States, education and training institutions and citizens in their efforts to adapt to the digital transition and help ensure a fair and inclusive recovery for all.

More information:
EPF Draft response: N/A

Please submit your comments by: 4 September 2020



European Medicines Agencies’ Network Strategy to 2025

EMA and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years that was released for a two-month public consultation. The draft strategy details how the European medicines agencies’ network can continue to enable the supply of safe and effective medicines that meet patients’ needs in the face of challenges posed by ever-accelerating developments in science, medicine, digital technologies, globalisation as well as emerging health threats, such as the COVID-19 pandemic.

More information:
EPF Draft response: